Forced downregulation of RACK1 inhibits glioma development by suppressing Src/Akt signaling activity

Peng,Renjun; Jiang,Bing; Ma,Jianrong; Ma,Zhiming; Wan,Xin; Liu,Hongwei; Chen,Zigui; Cheng,Quan; Chen,Rui

doi:10.3892/or.2013.2723

Forced downregulation of RACK1 inhibits glioma development by suppressing Src/Akt signaling activity

Authors:
- Renjun Peng
- Bing Jiang
- Jianrong Ma
- Zhiming Ma
- Xin Wan
- Hongwei Liu
- Zigui Chen
- Quan Cheng
- Rui Chen
View Affiliations

Affiliations: Department of Neurosurgery, Xiangya Hospital of Central South University, Changsha, Hunan 410078, P.R. China
Published online on: September 6, 2013 https://doi.org/10.3892/or.2013.2723
Pages: 2195-2202

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Glioma is the most common primary brain malignant tumor. Receptor for activated C-kinase 1 (RACK1) is widely expressed in the central nervous system, and regulates multiple cellular processes including cell survival, proliferation, migration and metastasis. However, the role of RACK1 in glioma has never been revealed. The present study, for the first time, showed that RACK1 expression was significantly higher in glioma tissues and cell lines when compared with that in normal brain tissues, and was positively associated with the malignancy of glioma. siRNA-induced RACK1 downregulation significantly suppressed the proliferation and invasion of human glioma U87 and CHG-5 cells, while it promoted their apoptosis by upregulating Bax expression and reducing Bcl-2 expression. Furthermore, forced downregulation of RACK1 notably inhibited tumor xenograft growth in nude mice. These findings suggest that RACK1 plays a critical role in the development and progression of glioma in vitro and in vivo. Moreover, siRNA-induced RACK1 downregulation markedly reduced the activity of Src/Akt signaling pathway, which plays an important role in the growth and behavior of human malignancies, indicating that siRNA-mediated RACK1 downregulation inhibited glioma probably via suppressing Src/Akt signaling activity. The present study highlighted the role of RACK1 in glioma, and demonstrated that RACK1 is a novel promising therapeutic target for glioma treatment.

View Figures

View References

1	Stewart LA: Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet. 359:1011–1018. 2002. View Article : Google Scholar : PubMed/NCBI
2	Zhu VF, Yang J, Lebrun DG and Li M: Understanding the role of cytokines in Glioblastoma Multiforme pathogenesis. Cancer Lett. 316:139–150. 2012. View Article : Google Scholar : PubMed/NCBI
3	Sathornsumetee S, Reardon DA, Desjardins A, Quinn JA, Vredenburgh JJ and Rich JN: Molecularly targeted therapy for malignant glioma. Cancer. 110:13–24. 2007. View Article : Google Scholar : PubMed/NCBI
4	Linz U: Commentary on effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial (Lancet Oncol 2009;10:459–466). Cancer. 116:1844–1846. 2010.PubMed/NCBI
5	Pulkkanen KJ and Yla-Herttuala S: Gene therapy for malignant glioma: current clinical status. Mol Ther. 12:585–598. 2005. View Article : Google Scholar : PubMed/NCBI
6	Dorn GW 2nd and Mochly-Rosen D: Intracellular transport mechanisms of signal transducers. Annu Rev Physiol. 64:407–429. 2002. View Article : Google Scholar : PubMed/NCBI
7	Adams DR, Ron D and Kiely PA: RACK1, a multifaceted scaffolding protein: structure and function. Cell Commun Signal. 9:222011. View Article : Google Scholar : PubMed/NCBI
8	Wan L, Xie Y, Su L, Liu Y, Wang Y and Wang Z: RACK1 affects morphine reward via BDNF. Brain Res. 1416:26–34. 2011. View Article : Google Scholar : PubMed/NCBI
9	Battaini F, Pascale A, Paoletti R and Govoni S: The role of anchoring protein RACK1 in PKC activation in the ageing rat brain. Trends Neurosci. 20:410–415. 1997. View Article : Google Scholar : PubMed/NCBI
10	Marqués N, Sesé M, Cánovas V, et al: Regulation of protein translation and c-Jun expression by prostate tumor overexpressed 1. Oncogene. Mar 04–2013.(Epub ahead of print). View Article : Google Scholar
11	Guo Y, Wang W, Wang J, et al: Receptor for activated C kinase 1 promotes hepatocellular carcinoma growth by enhancing mitogen-activated protein kinase kinase 7 activity. Hepatology. 57:140–151. 2013. View Article : Google Scholar : PubMed/NCBI
12	Cao XX, Xu JD, Xu JW, et al: RACK1 promotes breast carcinoma migration/metastasis via activation of the RhoA/Rho kinase pathway. Breast Cancer Res Treat. 126:555–563. 2011. View Article : Google Scholar : PubMed/NCBI
13	Trerotola M, Li J, Alberti S and Languino LR: Trop-2 inhibits prostate cancer cell adhesion to fibronectin through the β1 integrin-RACK1 axis. J Cell Physiol. 227:3670–3677. 2012.PubMed/NCBI
14	Wu J, Meng J, Du Y, et al: RACK1 promotes the proliferation, migration and invasion capacity of mouse hepatocellular carcinoma cell line in vitro probably by PI3K/Rac1 signaling pathway. Biomed Pharmacother. 67:313–319. 2013. View Article : Google Scholar : PubMed/NCBI
15	Ruan Y, Sun L, Hao Y, et al: Ribosomal RACK1 promotes chemoresistance and growth in human hepatocellular carcinoma. J Clin Invest. 122:2554–2566. 2012. View Article : Google Scholar : PubMed/NCBI
16	Li G, Ji XD, Gao H, et al: EphB3 suppresses non-small-cell lung cancer metastasis via a PP2A/RACK1/Akt signalling complex. Nat Commun. 3:6672012. View Article : Google Scholar : PubMed/NCBI
17	Lu F, Zhang C, Wu WJ and Wu YM: RACK1 downregulation suppresses migration and proliferation of neuroblastoma cell lines. Oncol Rep. 27:1646–1652. 2012.PubMed/NCBI
18	Li J, Guo Y, Feng X, et al: Receptor for activated C kinase 1 (RACK1): a regulator for migration and invasion in oral squamous cell carcinoma cells. J Cancer Res Clin Oncol. 138:563–571. 2012. View Article : Google Scholar : PubMed/NCBI
19	Wang F, Osawa T, Tsuchida R, Yuasa Y and Shibuya M: Downregulation of receptor for activated C-kinase 1 (RACK1) suppresses tumor growth by inhibiting tumor cell proliferation and tumor-associated angiogenesis. Cancer Sci. 102:2007–2013. 2011. View Article : Google Scholar : PubMed/NCBI
20	van Delft MF, Wei AH, Mason KD, et al: The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell. 10:389–399. 2006.PubMed/NCBI
21	Gelman IH: Src-family tyrosine kinases as therapeutic targets in advanced cancer. Front Biosci. 3:801–807. 2011.PubMed/NCBI
22	Aleshin A and Finn RS: SRC: a century of science brought to the clinic. Neoplasia. 12:599–607. 2010.PubMed/NCBI
23	Doan AT and Huttenlocher A: RACK1 regulates Src activity and modulates paxillin dynamics during cell migration. Exp Cell Res. 313:2667–2679. 2007. View Article : Google Scholar : PubMed/NCBI
24	Huveldt D, Lewis-Tuffin LJ, Carlson BL, et al: Targeting Src family kinases inhibits bevacizumab-induced glioma cell invasion. PLoS One. 8:e565052013. View Article : Google Scholar : PubMed/NCBI
25	Stedt H, Alasaarela L, Samaranayake H, et al: Specific inhibition of SRC kinase impairs malignant glioma growth in vitro and in vivo. Mol Ther Nucleic Acids. 1:e192012. View Article : Google Scholar : PubMed/NCBI
26	Creedon H and Brunton VG: Src kinase inhibitors: promising cancer therapeutics? Crit Rev Oncog. 17:145–159. 2012. View Article : Google Scholar : PubMed/NCBI
27	Sheppard K, Kinross KM, Solomon B, Pearson RB and Phillips WA: Targeting PI3 kinase/AKT/mTOR signaling in cancer. Crit Rev Oncog. 17:69–95. 2012. View Article : Google Scholar : PubMed/NCBI
28	Hemmings BA and Restuccia DF: PI3K-PKB/Akt pathway. Cold Spring Harb Perspect Biol. 4:a0111892012. View Article : Google Scholar : PubMed/NCBI
29	Mamidipudi V and Cartwright CA: A novel pro-apoptotic function of RACK1: suppression of Src activity in the intrinsic and Akt pathways. Oncogene. 28:4421–4433. 2009. View Article : Google Scholar : PubMed/NCBI